If Biogen Idec (BIIB)
follows the usual pattern, the launch of BG-12 for multiple sclerosis
isn't likely to generate huge investor enthusiasm (another example of
"buy the rumor, sell the news"). That's particularly true given
management's effort to take down the high end of BG-12 launch
expectations within the last month. Accordingly, while Biogen Idec is a
well-run franchise with a great niche in MS, and may well attract
attention from a larger pharma, the company may need another exciting
asset in its pipeline to keep up investor enthusiasm.
Continue to the full piece at Seeking Alpha:
Biogen Idec Has BG-12, But What Excites Investors Next?
No comments:
Post a Comment